<DOC>
	<DOCNO>NCT00152984</DOCNO>
	<brief_summary>The primary objective study demonstrate superiority tiotropium compare placebo treatment patient COPD concomitant diagnosis asthma</brief_summary>
	<brief_title>Efficacy Safety Tiotropium Patients With COPD Concomitant Diagnosis Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : Diagnosis COPD diagnosis asthma age 30 Current exsmokers cigarette smoke history least 10 packyears Treatment inhale steroid least 1 year study entry FEV1 increase 12 % 30 min . 400 mcg salbutamol document reversibility 12 % document past 5 year FEV1 increase 200 mL 30 min . 400 mcg salbutamol document increase 200 mL reversibility test within last 5 year Post bronchodilator FEV1 le 80 % predict normal ( ECCS ) visit 1 Post bronchodilator FEV1 le 70 % FVC visit 1 Exclusion criterion : Respiratory infection exacerbation 6 week prior Visit 1 runin period . Significant disease COPD asthma Myocardial infarction within last 6 month Unstable lifethreatening cardiac arrhythmia require intervention change therapy last year Hospitalisation heart failure ( NYHA Class III IV ) within last year History lifethreatening pulmonary obstruction , cystic fibrosis clinically evident bronchiectasis Known active tuberculosis History thoracotomy pulmonary resection History cancer within last 5 year ( exclude treat basal cell carcinoma ) Patients require oxygen therapy 1 hour per day Patients currently pulmonary rehabilitation programme complete programme within 4 week Visit 1 Known hypersensitivity anticholinergic drug lactose</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>